SNGX Soligenix, Inc. - Common Stock
NASDAQ · Biotechnology · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Aug 7, 2026
$0.37
· of 52w range
· above low
· to high
$0.2852w low
$1.9752w high
Market Cap (MRQ)
$8M
P/E
-0.2
EPS
$-2.14
Revenue
$119.4K
your badges
52W Range
$0–$2
Analyst Rating
BUY
Price Target
$1
P/E
-0.2
ROE
-311.2%
Net Profit Margin
·
Your badge strip is empty — pin a metric anywhere on this page.
SNGX Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$0.37
Market Cap (MRQ)
$8M
P/E
-0.2
EPS
$-2.14
Revenue
$119.4K
ROE
-311.2%
52W Range
$0–$2
SNGX Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
Stock splits
| Ex-date | Split | Type |
|---|---|---|
| June 6, 2024 | 1-for-16 | Reverse |
| Feb. 10, 2023 | 1-for-15 | Reverse |
| Oct. 7, 2016 | 1-for-10 | Reverse |
| Feb. 1, 2012 | 1-for-20 | Reverse |
| June 11, 1997 | 1-for-15 | Reverse |
10-Year Performance Revenue, net income, margins and EPS trends
Revenue$119.4K2021-12-31 → 2024-12-31
EPS$-2.142021-12-31 → 2025-12-31
Free Cash Flow$-10M2025-12-31 → 2025-12-31
Net margin·2021-12-31 → 2024-12-31
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | SNGX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E | -0.2 | · | · | · | |
| P/S | 8.1 | · | 12.6 | Overvalued | |
| P/B (MRQ) | 1.2 | · | · | · | |
| Price / FCF | -0.4 | · | · | · | |
| Price / Cash Flow | -0.4 | · | · | · | |
| Price / Tangible Book | 0.7 | · | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | SNGX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| ROA | -121.8% | · | -126.8% | In line | |
| ROE | -311.2% | · | -298.2% | Weak | |
| ROIC | -214.0% | · | · | · |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | SNGX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio (MRQ) | 2.8 | · | 2.6 | Strong liquidity |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
| Metric | 5Y trend | SNGX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue YoY | -85.8% | · | · | · | |
| Revenue CAGR 3Y | -47.5% | · | · | · |
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | SNGX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue / Employee | ≈$9.2K | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
2.1%
Next Report
Nov 05, 2026
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Aug 12, 2026 | $-0.12 | $-0.16 | 24.1% |
| March 31, 2026 | May 7, 2026 | $-0.28 | $-0.29 | 2.0% |
| Dec. 31, 2025 | $-0.28 | $-0.57 | 51.0% | |
| Sept. 30, 2025 | $-0.58 | $-0.57 | -2.5% | |
| June 30, 2025 | $-0.82 | $-0.94 | 12.6% | |
| March 31, 2025 | $-1.06 | $-0.68 | -55.1% | |
| Dec. 31, 2024 | $-1.14 | $-0.97 | -17.6% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | $119.4K | $839.4K | $948.9K | $824.3K | $2M | $5M | $5M | $5M | |
| Cost of Revenue | · | $119.4K | $742.0K | $550.8K | $728.6K | $2M | $4M | $5M | $4M | |
| Gross Profit | · | · | $97.3K | $398.1K | $95.6K | $538.5K | $1M | $643.7K | $1M | |
| R&D Expense | $7M | $5M | $3M | $8M | $8M | $10M | $8M | $7M | $6M | |
| SG&A Expense | $4M | $4M | $4M | $7M | $5M | $4M | $3M | $3M | $3M | |
| Operating Expenses | $12M | $9M | $8M | $15M | $13M | $19M | $12M | $10M | $9M | |
| Operating Income | $-12M | $-9M | $-8M | $-14M | $-13M | $-19M | $-11M | $-9M | $-8M | |
| Interest Income | · | · | · | · | · | · | $149.0K | $158.6K | · | |
| Other Non-op | $-11.7K | $549.8K | $-161.5K | $5.9K | $30.8K | $61.1K | $574.8K | $159.0K | · | |
| Pretax Income | $-12M | $-9M | $-8M | $-15M | $-13M | $-19M | $-10M | $-9M | $-8M | |
| Income Tax | $-506.6K | $-409.1K | $-2M | $-1M | $-864.7K | $-836.9K | $-610.7K | · | $-416.8K | |
| Net Income | $-11M | $-8M | $-6M | $-14M | $-13M | $-18M | $-9M | $-9M | $-7M | |
| EPS (Basic) | $-2.14 | $-4.98 | $-12.66 | $-4.81 | $-4.69 | $-0.64 | · | · | · | |
| EPS (Diluted) | $-2.14 | $-4.98 | $-12.66 | $-4.81 | $-4.69 | $-0.64 | · | · | · | |
| Shares (Basic) | 5,188,799 | 1,660,413 | 484,995 | 2,871,345 | 2,675,488 | 27,486,949 | · | · | · | |
| Shares (Diluted) | 5,188,799 | 1,660,413 | 484,995 | 2,871,345 | 2,675,488 | 27,486,949 | · | · | · | |
| EBITDA | $-12M | $-9M | $-8M | $-14M | $-13M | $-19M | $-10M | $-9M | · |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | · | · | · | · | $26M | $19M | $5M | $9M | $8M | |
| Prepaid Expense | $894.3K | $905.3K | $866.0K | $274.2K | $282.9K | $225.5K | $609.7K | $157.3K | $263.3K | |
| Current Assets | $9M | $9M | $10M | $14M | $27M | $19M | $7M | $10M | $9M | |
| PP&E (Net) | $8.8K | $6.1K | $11.9K | $18.5K | $22.2K | $23.5K | $36.1K | $19.6K | $37.2K | |
| PP&E (Gross) | · | · | · | · | · | $154.8K | $135.0K | · | · | |
| Accum. Depreciation | · | · | $121.3K | $114.8K | $167.8K | $154.8K | · | · | · | |
| Intangibles | · | · | · | · | · | · | $19.7K | $46.9K | $74.0K | |
| Other Non-current Assets | · | · | · | · | $7.8K | $23.2K | $38.8K | · | · | |
| Total Assets | $9M | $9M | $10M | $14M | $27M | $20M | $8M | $10M | $10M | |
| Accounts Payable | $1M | $667.9K | $1M | $4M | $3M | $2M | $3M | $2M | $2M | |
| Accrued Liabilities | $2M | $2M | $2M | $2M | $3M | $3M | $3M | $2M | $1M | |
| Short-term Debt | · | · | · | · | · | $325.0K | · | · | · | |
| Current Liabilities | $4M | $5M | $6M | $17M | $6M | $6M | $6M | $4M | $3M | |
| Capital Leases | $244.1K | · | $111.9K | $233.6K | · | · | · | · | · | |
| Total Liabilities | $4M | $5M | $7M | $17M | $16M | $16M | $6M | $4M | · | |
| Long-term Debt | · | $0 | $1M | $0 | · | · | · | · | · | |
| Total Debt | · | · | · | · | · | $325.0K | · | · | · | |
| Common Stock | $10.1K | $2.5K | $649 | $2.9K | $2.9K | $30.6K | $21.8K | $17.7K | $8.7K | |
| Paid-in Capital | $250M | $238M | $228M | $217M | $216M | $197M | $177M | $172M | $164M | |
| Retained Earnings | $-245M | $-234M | $-226M | $-220M | $-206M | $-193M | $-176M | $-166M | $-157M | |
| AOCI | $45.8K | $45.8K | $22.2K | $24.7K | $41.9K | $-24.3K | $-45.0K | $-3.7K | · | |
| Stockholders' Equity | $5M | $4M | $3M | $-2M | $11M | $4M | $1M | $6M | $6M | |
| Liabilities + Equity | $9M | $9M | $10M | $14M | $27M | $20M | $8M | $10M | $10M | |
| Shares Outstanding | 10,086,130 | 2,514,499 | 648,761 | 2,908,578 | 2,858,244 | 30,643,656 | 21,753,124 | 17,682,839 | 8,730,640 |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | $34.2K | $62.4K | $54.5K | $44.1K | $68.6K | |
| Stock-based Comp | $587.6K | $329.8K | $370.2K | $333.4K | $361.6K | $409.9K | $376.3K | $380.9K | $489.8K | |
| Amort. of Intangibles | · | · | · | · | · | $19.7K | $27.2K | $27.1K | $52.7K | |
| Other Non-cash | · | · | · | · | $415.6K | $6M | $1M | $1M | · | |
| Operating Cash Flow | $-10M | $-8M | $-9M | $-13M | $-12M | $-11M | $-8M | $-7M | $-7M | |
| CapEx | $5.9K | · | · | · | · | · | · | · | · | |
| Investing Cash Flow | $-5.9K | · | · | $-13.1K | $-11.8K | $-7.1K | $-24.7K | $-925 | $-26.3K | |
| Financing Cash Flow | $10M | $8M | $4M | $76.8K | $19M | $25M | $4M | $8M | $6M | |
| Net Change in Cash | $116.6K | $-626.6K | $-5M | $-13M | $7M | $13M | $-4M | $1M | $-963.1K | |
| Free Cash Flow | $-10M | · | · | · | · | · | · | · | · |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | 11.6% | 41.9% | 11.6% | 22.8% | 22.9% | 12.3% | · | |
| Operating Margin | · | -7907.7% | -917.1% | -1500.5% | -1594.2% | -787.8% | -227.7% | -172.8% | · | |
| Net Margin | · | -6925.1% | -731.6% | -1454.1% | -1522.7% | -749.7% | -202.1% | -169.8% | · | |
| Pretax Margin | · | -7267.8% | -942.2% | -1575.8% | -1627.6% | -785.2% | -215.3% | -169.8% | · | |
| EBITDA Margin | · | -7907.7% | -917.1% | -1500.5% | -1590.1% | -785.1% | -226.5% | -172.0% | · | |
| ROA | -121.8% | -85.0% | -51.0% | -67.1% | -53.7% | -127.9% | -102.4% | -88.8% | · | |
| ROE | -311.2% | -164.5% | -182.1% | 1918.0% | -97.4% | -317.4% | -452.6% | -114.5% | · | |
| ROIC | -214.0% | -218.4% | -237.0% | 531.8% | -114.7% | -436.4% | -679.1% | · | · |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.4 | 1.8 | 1.5 | 0.8 | 4.2 | 3.2 | 1.2 | 2.5 | · | |
| Quick Ratio | · | · | · | · | 4.1 | 3.1 | 0.9 | 2.1 | · | |
| Debt / Equity | · | · | · | · | · | 0.1 | · | · | · |
Efficiency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | 0.0 | 0.1 | 0.0 | 0.0 | 0.2 | 0.5 | 0.5 | · |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.52 | $1.64 | $0.24 | $-0.85 | $0.25 | $0.12 | $0.07 | $0.36 | · | |
| Revenue / Share | · | $0.07 | $0.11 | $0.33 | $0.02 | · | · | · | · | |
| Cash Flow / Share | $-1.98 | $-5.06 | $-1.11 | $-4.41 | $-0.29 | · | · | · | · | |
| Cash / Share | · | · | · | · | $0.61 | $0.61 | $0.25 | $0.51 | · | |
| EPS (TTM) | $-2.14 | $-4.98 | $-12.66 | $-4.81 | $-4.69 | $-0.64 | · | · | · |
Growth Rates
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | · | -85.8% | -11.6% | 15.1% | -65.1% | · | · | · | · | |
| Revenue CAGR 3Y | · | -47.5% | -29.1% | · | · | · | · | · | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $456.7K | $119.4K | $839.4K | $948.9K | $824.3K | $2M | $5M | $5M | $5M | |
| Net Income TTM | $-11M | $-8M | $-6M | $-14M | $-13M | $-18M | $-9M | $-9M | $-7M | |
| Market Cap | $14M | $7M | $126M | $314M | $6.79B | $9.41B | $7.57B | $3.65B | · | |
| Enterprise Value | · | · | · | · | · | $9.40B | · | · | · | |
| P/E | -0.6 | -0.5 | -1.0 | -22.5 | -33.8 | -480.0 | · | · | · | |
| P/S | 29.6 | 56.9 | 150.4 | 331.0 | 8239.0 | 3989.8 | 1635.0 | 696.3 | · | |
| P/B | 2.6 | 1.6 | 50.0 | -127.1 | 633.3 | 2515.8 | 5195.2 | 581.2 | · | |
| P / Tangible Book | 2.6 | 1.6 | 50.0 | · | 633.3 | 2515.8 | · | · | · | |
| P / Cash Flow | -1.3 | -0.8 | -14.7 | -24.8 | -578.5 | -821.8 | -1008.1 | -503.8 | · | |
| P / FCF | -1.3 | · | · | · | · | · | · | · | · | |
| EV / EBITDA | · | · | · | · | · | -507.2 | · | · | · | |
| EV / Revenue | · | · | · | · | · | 3982.0 | · | · | · | |
| Earnings Yield | -159.7% | -184.4% | -104.1% | -4.5% | -3.0% | -0.21% | · | · | · |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | · | · | · | · | $0 | $0 | $2.3K | $117.0K | $244.8K | $130.4K | $206.9K | $257.2K | $366.1K | $166.1K | |
| Cost of Revenue | · | · | · | · | · | · | $0 | $0 | $2.3K | $117.0K | $221.5K | $110.4K | $184.0K | $226.0K | $135.9K | $129.4K | |
| Gross Profit | · | · | · | · | · | · | · | · | · | · | $23.3K | $20.0K | $22.9K | $31.1K | $230.2K | $36.7K | |
| R&D Expense | $974.1K | $2M | $2M | $2M | $2M | $2M | $3M | $968.7K | $501.2K | $1M | $777.5K | $826.0K | $762.7K | $946.5K | $2M | $2M | |
| SG&A Expense | $1M | $1M | $1M | $996.6K | $1M | $1M | $1M | $896.5K | $1M | $1M | $1M | $973.0K | $890.5K | $1M | $1M | $1M | |
| Operating Expenses | $2M | $3M | $3M | $3M | $3M | $3M | $4M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $4M | $3M | |
| Operating Income | $-2M | $-3M | $-3M | $-3M | $-3M | $-3M | $-4M | $-2M | $-2M | $-2M | $-2M | $-2M | $-2M | $-2M | $-4M | $-3M | |
| Other Non-op | $58.5K | $-1.5K | $-166 | $-2.8K | $-7.9K | $-788 | $245.6K | $67.0K | $64.2K | $172.9K | $-204.7K | $0 | $2.4K | $40.9K | · | · | |
| Pretax Income | $-2M | $-3M | $-3M | $-3M | $-3M | $-3M | $-3M | $-2M | $-2M | $-2M | $-2M | $-2M | $-2M | $-2M | $-4M | $-3M | |
| Income Tax | · | · | · | · | · | · | · | · | · | · | $-606.6K | $0 | $0 | $-1M | $0 | $-1M | |
| Net Income | $-2M | $-3M | $-3M | $-3M | $-3M | $-3M | $-3M | $-2M | $-2M | $-2M | $-2M | $-2M | $-2M | $-1M | $-4M | $-3M | |
| EPS (Basic) | $-0.12 | $-0.28 | $0.23 | $-0.58 | $-0.82 | $-0.97 | $0.02 | $-0.78 | $-1.31 | $-2.91 | $-6.18 | $-2.56 | $-3.56 | $-0.36 | $-1.31 | $-1.15 | |
| EPS (Diluted) | $-0.12 | $-0.28 | $0.23 | $-0.58 | $-0.82 | $-0.97 | $0.02 | $-0.78 | $-1.31 | $-2.91 | $-6.18 | $-2.56 | $-3.56 | $-0.36 | $-1.31 | $-1.15 | |
| Shares (Basic) | 15,951,949 | 10,164,898 | · | 4,329,649 | 3,278,677 | 3,049,625 | · | 2,203,929 | 1,258,985 | 657,698 | · | 648,860 | 453,035 | 2,914,929 | · | 2,872,262 | |
| Shares (Diluted) | 15,951,949 | 10,164,898 | · | 4,329,649 | 3,278,677 | 3,049,625 | · | 2,203,929 | 1,258,985 | 657,698 | · | 648,860 | 453,035 | 2,914,929 | · | 2,872,262 | |
| EBITDA | $-2M | $-3M | · | $-3M | $-3M | $-3M | · | $-2M | $-2M | $-2M | · | $-2M | $-2M | $-2M | · | $-3M |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prepaid Expense | $355.5K | $437.1K | $894.3K | $355.6K | $191.1K | $299.7K | $905.3K | $340.3K | $244.5K | $451.9K | $866.0K | $584.4K | $171.3K | $213.3K | $274.2K | $396.4K | |
| Current Assets | $10M | $7M | $9M | $11M | $5M | $8M | $9M | $10M | $10M | $8M | $10M | $11M | $13M | $11M | $14M | $17M | |
| PP&E (Net) | $6.6K | $7.7K | $8.8K | $7.8K | $8.1K | $5.5K | $6.1K | $7.2K | $8.8K | $10.3K | $11.9K | $13.5K | $15.1K | $16.7K | $18.5K | $21.5K | |
| Accum. Depreciation | · | · | · | · | · | · | · | · | · | · | · | $119.7K | $118.1K | $116.6K | $114.8K | $111.7K | |
| Total Assets | $10M | $7M | $9M | $11M | $6M | $8M | $9M | $10M | $10M | $8M | $10M | $11M | $14M | $11M | $14M | $18M | |
| Accounts Payable | $1M | $828.7K | $1M | $1M | $650.0K | $599.7K | $667.9K | $891.2K | $2M | $1M | $1M | $1M | $2M | $3M | $4M | $4M | |
| Accrued Liabilities | $2M | $3M | $2M | $2M | $3M | $3M | $2M | $1M | $2M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Current Liabilities | $4M | $4M | $4M | $3M | $4M | · | $5M | $5M | $6M | $7M | $6M | $6M | $6M | $11M | $17M | $10M | |
| Capital Leases | $182.1K | $213.4K | $244.1K | $273.9K | $302.6K | · | · | $11.5K | $45.7K | $79.1K | $111.9K | $143.7K | $174.3K | $204.3K | $233.6K | $262.1K | |
| Total Liabilities | $4M | $4M | $4M | $4M | $4M | $4M | $5M | $5M | $6M | $7M | $7M | $7M | $8M | $14M | $17M | $17M | |
| Long-term Debt | · | · | · | · | · | · | · | · | · | · | $1M | $1M | $2M | · | $0 | · | |
| Common Stock | $21.6K | $10.5K | $10.1K | $9.9K | $3.5K | $3.2K | $2.5K | $2.3K | $1.5K | $10.5K | $649 | $10.4K | $9.8K | $2.9K | $2.9K | $43.1K | |
| Paid-in Capital | $256M | $251M | $250M | $250M | $241M | $241M | $238M | $237M | $233M | $228M | $228M | $228M | $228M | $217M | $217M | $217M | |
| Retained Earnings | $-250M | $-248M | $-245M | $-242M | $-240M | $-237M | $-234M | $-231M | $-229M | $-228M | $-226M | $-224M | $-222M | $-221M | $-220M | $-216M | |
| AOCI | $45.8K | $45.8K | $45.8K | $45.8K | $45.8K | $45.8K | $45.8K | $37.5K | $27.6K | $24.1K | $22.2K | $24.3K | $6.1K | $12.6K | $24.7K | $25.5K | |
| Stockholders' Equity | $7M | $3M | $5M | $8M | $2M | $4M | $4M | $6M | $3M | $768.4K | $3M | $4M | $6M | $-3M | $-2M | $1M | |
| Liabilities + Equity | $10M | $7M | $9M | $11M | $6M | $8M | $9M | $10M | $10M | $8M | $10M | $11M | $14M | $11M | $14M | $18M | |
| Shares Outstanding | 21,637,479 | 10,518,269 | 10,086,130 | 9,861,130 | 3,504,950 | 3,183,992 | 2,514,499 | 2,295,304 | 1,542,480 | 10,524,437 | 648,761 | 10,378,238 | 9,841,854 | 2,929,773 | 2,908,578 | 43,105,191 |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $116.0K | $121.2K | $320.1K | $104.3K | $99.5K | $63.6K | $155.5K | $56.6K | $57.7K | $60.0K | $141.1K | $65.4K | $90.0K | $73.6K | $112.7K | $70.7K | |
| Operating Cash Flow | $-2M | $-2M | $-3M | $-3M | $-3M | $-2M | $-2M | $-3M | $-2M | $-1M | $-2M | $-3M | $-2M | $-2M | $-4M | $-3M | |
| CapEx | · | · | $2.0K | $608 | · | · | · | · | · | · | · | · | · | · | · | · | |
| Investing Cash Flow | · | · | $-2.0K | $-608 | · | · | · | · | · | · | · | · | · | · | $0 | $0 | |
| Financing Cash Flow | $5M | $451.0K | $157.9K | $8M | $545.6K | $1M | $242.9K | $3M | $4M | $-9.0K | $-46.2K | $-175.3K | $5M | $-931.6K | · | · | |
| Net Change in Cash | $4M | $-2M | $-3M | $5M | $-2M | $-522.3K | $-2M | $427.6K | $2M | $-1M | $-2M | $-3M | $3M | $-3M | $-4M | $-3M |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | · | · | · | · | · | · | · | · | · | 15.3% | 11.1% | 12.1% | · | 22.1% | |
| Operating Margin | · | · | · | · | · | · | · | · | -74495.1% | -1809.0% | · | -1363.9% | -787.9% | -836.3% | · | -1854.6% | |
| Net Margin | · | · | · | · | · | · | · | · | -70217.9% | -1636.6% | · | -1274.7% | -779.0% | -406.8% | · | -1991.7% | |
| Pretax Margin | · | · | · | · | · | · | · | · | -70217.9% | -1636.6% | · | -1274.7% | -779.0% | -858.3% | · | -1991.7% | |
| EBITDA Margin | · | · | · | · | · | · | · | · | -74495.1% | -1809.0% | · | -1363.9% | -787.9% | -836.3% | · | -1854.6% | |
| ROA | -24.4% | -38.5% | · | -23.2% | -34.6% | -41.0% | · | -15.8% | -13.9% | -20.0% | · | -11.4% | -9.2% | -6.0% | · | -13.9% | |
| ROE | -46.9% | -84.3% | · | -37.4% | -102.1% | -147.8% | · | -33.9% | -35.5% | 146.3% | · | -63.3% | -32.2% | -65.4% | · | -41.1% | |
| ROIC | · | · | · | · | · | · | · | · | · | · | · | · | · | 30.1% | · | -194.4% |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.8 | 1.8 | · | 3.2 | 1.5 | · | · | 2.3 | 1.5 | 1.1 | · | 2.0 | 2.3 | 0.9 | · | 1.8 |
Efficiency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | · | · | · | · | · | · | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.31 | $0.29 | · | $0.77 | $0.52 | $1.13 | · | $2.59 | $2.25 | $0.07 | · | $0.41 | $0.59 | $-1.16 | · | $0.02 | |
| Revenue / Share | · | · | · | · | · | · | · | · | $0.00 | $0.01 | · | $0.01 | $0.03 | $0.09 | · | $0.00 | |
| Cash Flow / Share | · | $-0.23 | · | · | · | $-0.61 | · | · | · | $-0.13 | · | · | · | $-0.74 | · | · | |
| EPS (TTM) | $-0.75 | $-1.45 | · | $-2.35 | $-2.55 | $-3.04 | · | $-11.18 | $-12.96 | $-15.21 | · | $-7.79 | $-6.38 | $-3.65 | · | $-7.99 |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $119.4K | $119.4K | · | $119.4K | $119.4K | $119.4K | · | $364.2K | $494.6K | $699.2K | · | $960.6K | $996.3K | $1M | · | $858.5K | |
| Net Income TTM | $-10M | $-11M | · | $-11M | $-10M | $-9M | · | $-7M | $-7M | $-7M | · | $-8M | $-10M | $-10M | · | $-15M | |
| Market Cap | $9M | $12M | · | $11M | $5M | $7M | · | $9M | $4M | $101M | · | $93M | $110M | $92M | · | $4.55B | |
| P/E | -0.5 | -0.8 | · | -0.5 | -0.5 | -0.7 | · | -0.4 | -0.2 | -0.6 | · | -1.2 | -1.8 | -8.6 | · | -13.2 | |
| P/S | 72.5 | 104.0 | · | 95.8 | 38.5 | 57.3 | · | 25.0 | 8.0 | 144.5 | · | 96.8 | 110.6 | 90.7 | · | 5302.2 | |
| P/B | 1.3 | 4.0 | · | 1.5 | 2.5 | 1.9 | · | 1.5 | 1.1 | 131.5 | · | 22.0 | 19.0 | -27.3 | · | 4410.8 | |
| P / Tangible Book | 1.3 | 4.0 | · | 1.5 | 2.5 | 1.9 | · | 1.5 | 1.1 | 131.5 | · | 22.0 | 19.0 | · | · | 4410.8 | |
| P / Cash Flow | · | -5.3 | · | · | · | -3.7 | · | · | · | -75.3 | · | · | · | -42.6 | · | · | |
| Earnings Yield | -187.5% | -122.9% | · | -202.6% | -194.7% | -141.4% | · | -281.6% | -502.3% | -158.4% | · | -86.9% | -57.0% | -11.6% | · | -7.6% |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|
| Revenue | · | · | · | $119.4K | · |
| Operating Margin % | · | · | · | -7907.7% | · |
| Net Income | $-11M | · | · | $-8M | · |
| Diluted EPS | $-2.14 | · | · | $-4.98 | · |
| Metric | 2025-12-31 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|
| Current Ratio | 2.4 | · | · | 1.8 | · |
| Metric | 2025-12-31 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|
| Free Cash Flow | $-10M | · | · | · | · |
Institutional owners (13F) 20 filers · $460K total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
20
Value held
$460K
New positions
6
Exited positions
3
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 6 (+2 vs prior Q) | 3 (-2 vs prior Q) | 3 (0 vs prior Q) | 3 (0 vs prior Q) | +673K |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| VANGUARD GROUP INC | $114,527 | 85,468 | 24.89% | Shares |
| CITADEL ADVISORS LLC | $82,965 | 209,507 | 18.03% | Shares |
| JANE STREET GROUP, LLC | $82,166 | 207,492 | 17.86% | Shares |
| XTX Topco Ltd | $62,219 | 157,119 | 13.52% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $47,624 | 120,267 | 10.35% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $32,078 | 81,005 | 6.97% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $21,350 | 53,914 | 4.64% | Shares |
| NORTHERN TRUST CORP | $15,066 | 38,046 | 3.27% | Shares |
| MORGAN STANLEY | $1,422 | 3,592 | 0.31% | Shares |
| JONES FINANCIAL COMPANIES LLLP | $507 | 1,236 | 0.11% | Shares |
| JPMORGAN CHASE & CO | $98 | 245 | 0.02% | Shares |
| Plante Moran Financial Advisors, LLC | $83 | 209 | 0.02% | Shares |
| Virtu Financial LLC | $24 | 60,903 | 0.01% | Shares |
| CWM, LLC | $7 | 6 | 0.00% | Shares |
| ALBION FINANCIAL GROUP /UT | $1 | 1 | 0.00% | Shares |
| SBI Securities Co., Ltd. | $1 | 2 | 0.00% | Shares |
| OSAIC HOLDINGS, INC. | $0 | 1 | 0.00% | Shares |
| ROYAL BANK OF CANADA | $0 | 5 | 0.00% | Shares |
| Caitong International Asset Management Co., Ltd | $0 | 1 | 0.00% | Shares |
| Motiv8 Investments LLC | $0 | 3 | 0.00% | Shares |
Activists & 5%+ owners 16 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Paolo Cavazza (2), Essetifin S.p.A. (2), Leadiant Biosciences, Inc. (2), Enrico Cavazza (2), Francesca Cavazza (2), Silvia Cavazza (2), Martina Cavazza Preta (2) ×29 filings | Dec. 1, 2017 | · | Initial filing | · | SEC |
| RANDAL J. KIRK, THIRD SECURITY, LLC, NRM VII HOLDINGS I, LLC, INTREXON CORPORATION ×6 filings | June 16, 2017 | · | Initial filing | · | SEC |
| Cyrille F. Buhrman | July 2, 2007 | · | Initial filing | Passive investment | SEC |
| Elan Corporation, plc, Elan International Services Ltd., Elan Pharmaceutical Investments, Ltd. ×3 filings | Feb. 13, 2006 | · | Initial filing | · | SEC |
| Undisclosed reporting person | Feb. 19, 2004 | · | Initial filing | · | SEC |
| Undisclosed reporting person | Feb. 19, 2004 | · | Initial filing | · | SEC |
| Undisclosed reporting person | Feb. 19, 2004 | · | Initial filing | · | SEC |
| Undisclosed reporting person, Undisclosed reporting person | Feb. 13, 2004 | · | Initial filing | · | SEC |
| Undisclosed reporting person, Undisclosed reporting person | Feb. 13, 2004 | · | Initial filing | · | SEC |
| Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person | Feb. 13, 2004 | · | Initial filing | Passive investment | SEC |
| Undisclosed reporting person, Undisclosed reporting person | Feb. 13, 2004 | · | Initial filing | · | SEC |
| Undisclosed reporting person, Undisclosed reporting person | Feb. 6, 2004 | · | Initial filing | Board campaign | SEC |
| Undisclosed reporting person, Undisclosed reporting person | Feb. 6, 2004 | · | Initial filing | Board campaign | SEC |
| Undisclosed reporting person, Undisclosed reporting person | Feb. 6, 2004 | · | Initial filing | Board campaign | SEC |
| Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person | May 23, 2002 | · | Initial filing | Passive investment | SEC |
| Undisclosed reporting person | May 23, 2002 | · | Initial filing | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 36 insiders · 13 officers · 21 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Christopher J Schaber | CHAIRMAN, CEO AND PRESIDENT | Dec. 11, 2025 A | 15,511 | 1 | 0 | $19,974 |
| Michael T Sember | Chief Executive Officer | April 10, 2006 A | 180,440 | 0 | 0 | $0 |
| Jonathan L. Guarino | CFO | Dec. 11, 2025 A | 11,000 | 0 | 0 | $0 |
| Karen R Krumeich | SVP and CFO | Dec. 13, 2018 A | · | 0 | 0 | $0 |
| Joseph Michael Warusz | VP of Finance/Acting CFO | Dec. 31, 2015 A | 12,955 | 0 | 0 | $0 |
| Evan Myrianthopoulos | Sr VP and CFO | Dec. 1, 2011 A | 224,780 | 0 | 0 | $0 |
| Oreola Donini | CSO | Dec. 11, 2025 A | · | 0 | 0 | $0 |
| Richard Straube | CMO (Consulting) | Dec. 11, 2025 A | 8,000 | 0 | 0 | $0 |
| Robert N Brey | Chief Scientific Off., Sr. VP | Dec. 5, 2013 A | · | 0 | 0 | $0 |
| Kevin Horgan | Chief Medical Officer & Sr. VP | Sept. 25, 2013 A | · | 0 | 0 | $0 |
| Brian L Hamilton | Chief Medical Officer & Sr VP | Sept. 23, 2010 A | · | 0 | 0 | $0 |
| Christopher P. Schnittker | VP-Admin., Controller | Sept. 23, 2010 A | · | 0 | 0 | $0 |
| James Clavijo | Controller/Treasurer | Dec. 18, 2008 A | 88,191 | 0 | 0 | $0 |
| Diane L. Parks | Director | Sept. 17, 2026 A | 14,940 | 0 | 0 | $0 |
| Jerome B Zeldis | Director | Sept. 17, 2026 A | 22,917 | 0 | 0 | $0 |
| Robert J. Rubin | Director | Sept. 17, 2026 A | 4,385 | 0 | 0 | $0 |
| Anthony Gregg Lapointe | Director | Sept. 17, 2026 A | 73,781 | 0 | 0 | $0 |
| Timothy R. Cote | Director | May 3, 2023 A | · | 0 | 0 | $0 |
| Mark E. Pearson | Director | Sept. 6, 2019 A | 78,338 | 0 | 0 | $0 |
| Keith L Brownlie | Director | Sept. 27, 2018 A | 50,000 | 0 | 0 | $0 |
| Marco Maria Brughera | Director | June 8, 2017 A | 2,750 | 0 | 0 | $0 |
| Virgil Thompson | Director | June 22, 2011 A | · | 0 | 0 | $0 |
| Tamar D Howson | Director | June 22, 2011 A | · | 0 | 0 | $0 |
| Cyrille F Buhrman | Director | June 4, 2009 A | · | 0 | 0 | $0 |
| James S Kuo | Director | June 4, 2009 A | · | 0 | 0 | $0 |
| KANZER STEVE H | Director | Feb. 9, 2007 P | 1,282,203 | 0 | 0 | $0 |
| T J Madison | Director | Jan. 10, 2006 A | · | 0 | 0 | $0 |
| Alexander P Haig | Director | Jan. 10, 2006 A | · | 0 | 0 | $0 |
| Peter Salomon | Director | Sept. 9, 2004 A | 415,000 | 0 | 0 | $0 |
| Arthur Asher Kornbluth | Director | Sept. 9, 2004 A | · | 0 | 0 | $0 |
| Peter Salomon MD | Director | Sept. 15, 2003 A | · | 0 | 0 | $0 |
| Paolo Cavazza | 10% owner | Dec. 20, 2012 J | 3,282,929 | 0 | 0 | $0 |
| Claudio Cavazza | 10% owner | June 18, 2010 J | 54,227,816 | 0 | 0 | $0 |
| Biotex Pharma Investments, LLC | 10% owner | Sept. 18, 2009 D | 18,750,000 | 0 | 0 | $0 |
| Larry Kessel | · | Sept. 9, 2004 A | · | 0 | 0 | $0 |
| Alexander M Jr General Usa Ret Haig | · | Sept. 9, 2004 A | · | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 1 ETF
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| VXF · VANGUARD INDEX FUNDS | 0.00% | 81,005 SH | Aug. 19, 2026 | Daily |
SNGX Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 7 analysts
BUY
Median target
$1.38
+276.3%
2 28.6%
Strong Buy
4 57.1%
Buy
1 14.3%
Hold
0 0.0%
Sell
0 0.0%
Strong Sell
12-Month Price Target
2 analysts · 2026-10-02Mean target $1.38 +276.3%
← Below all targets
Current price $0.37
Low$1.25
Mean$1.38
High$1.50
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| SNGX | $14M | -0.6 | -85.8% | · | -311.2% | · |
| FBLG | · | -0.5 | · | · | · | · |
| LGVN | · | -0.4 | -49.9% | -1893.6% | -247.7% | 67.0% |
| ENSC | $4M | -0.2 | -2.8% | -200.9% | -294.0% | · |
| KALA | $15M | -0.2 | · | · | -1423.8% | · |
| SKYE | $25M | -0.5 | · | · | -175.6% | · |
| IMNN | $13M | -0.6 | · | · | -298.2% | · |
| BIAF | · | · | · | · | · | · |
| ACXP | $6M | -0.5 | · | · | -180.3% | · |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Aug 7, 2026